Cargando…

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers

INTRODUCTION: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here we investigate the role of BRCA1-IRIS as a novel treatment target for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanchard, Zannel, Paul, Bibbin T, Craft, Barbara, ElShamy, Wael M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322455/ https://www.ncbi.nlm.nih.gov/pubmed/25583261 http://dx.doi.org/10.1186/s13058-014-0512-9

Ejemplares similares

BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells
por: Shimizu, Yoshiko, et al.
Publicado: (2012)

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions
por: Sinha, Abhilasha, et al.
Publicado: (2016)

The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
por: Ryan, Daniel, et al.
Publicado: (2019)

The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression
por: ElShamy, Wael M.
Publicado: (2016)

A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment
por: Ryan, Daniel, et al.
Publicado: (2017)

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
por: Bogan, Danielle, et al.
Publicado: (2017)

Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment
por: Ryan, Daniel, et al.
Publicado: (2017)

BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers
por: Shimizu, Yoshiko, et al.
Publicado: (2012)

Geminin Overexpression Promotes Imatinib Sensitive Breast Cancer: A Novel Treatment Approach for Aggressive Breast Cancers, Including a Subset of Triple Negative
por: Blanchard, Zannel, et al.
Publicado: (2014)

Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis
por: Ryan, Daniel, et al.
Publicado: (2019)

Geminin overexpression induces mammary tumors via suppressing cytokinesis
por: Blanchard, Zannel, et al.
Publicado: (2011)

Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers
por: Ananthula, Suryatheja, et al.
Publicado: (2016)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
por: Shakir, Abdur R.
Publicado: (2014)

Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors?
por: ElShamy, Wael M., et al.
Publicado: (2016)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Research advances and new challenges in overcoming triple-negative breast cancer
por: Zong, Yu, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
por: Emborgo, Trisha S, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer
por: Moreno, Marcelo, et al.
Publicado: (2023)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy
por: Toss, Angela, et al.
Publicado: (2020)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells
por: Gote, Vrinda, et al.
Publicado: (2021)

Penfluridol overcomes paclitaxel resistance in metastatic breast cancer
por: Gupta, Nehal, et al.
Publicado: (2019)

Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer
por: Yadav, Sushma, et al.
Publicado: (2013)

Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward
por: Alaouna, Mohammed, et al.
Publicado: (2023)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_uospc84npi906mesh8rl5fgnlp